NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: University Hospital, Bordeaux
Conditions: Parkinson Disease, Multiple System Atrophy
Interventions: voice recordings
Countries: France
Parkinson's disease (PD) is the second most common neurodegenerative disease. Multiple system atrophy (MSA) is a relentlessly progressing rare neurodegenerative disease of unknown etiology. The differential diagnosis between the MSA-Parkinsonism (MSA-P) subtype and PD can be very challenging in early disease stages, while early diagnostic certitude is important for the patient because of the diverging prognosis. At the time being, there exists no validated objective biomarker to guide the clinician. Dysarthria is a common early symptom in both diseases and of different origin. The ambition and the originality of this project are to develop a digital voice-based tool for objective discrimination between PD and MSA-P.
Sex: ALL
Age: 30 Years to 80 Years
Healthy volunteers: Yes
Study type: INTERVENTIONAL
* Inclusion criteria:
* Age from 30 to 80 years old
* Signed informed consent
* Affiliated to social security
* Patient with PD :
* Diagnosis of idiopathic Parkinson's disease (PD) according to criteria (Postuma et al., 2015)
* Patient PD : Hoehn\&Yahr stage between 1 and 2
* Patient with or without mild to moderate speech troubles: MDS-UPDRS III item 1 ≤ 2
* Patients with MSA-P :
* Diagnosis of Multiple Atrophy System (MSA) Parkinsonian form possible or probable according to current consensus criteria (Gilman et al., 2008)
* Patient MSA-P: score of part IV of the UMSARS ≤ 3 points
* Patient with or without mild to moderate speech troubles: UMSARS II item 2 ≤ 2
* Controls :
* Absence of neurologic and oto-rhino-laryngologic disease
* Exclusion criteria :
* Deafs and/or mutes
* Patient with speech disorders which are not related to MSA or PD
* Person under safeguard justice, guardianship- Bordeaux, France
- Toulouse, France